<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04885530</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00107921</org_study_id>
    <secondary_id>3U24TR001608-05W1</secondary_id>
    <nct_id>NCT04885530</nct_id>
  </id_info>
  <brief_title>ACTIV-6: COVID-19 Study of Repurposed Medications</brief_title>
  <official_title>ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susanna Naggie, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of repurposed medications (study&#xD;
      drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.&#xD;
      Participants will receive either study drug or placebo. They will self-report any new or&#xD;
      worsening symptoms or medical events they may experience while taking study drug or placebo.&#xD;
      This study is intended to be all remote with no in person visits, unless the study team feels&#xD;
      it is in the best interest of a participant to see them in person.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that&#xD;
      first emerged in December 2019 and has since caused a global pandemic unseen in almost a&#xD;
      century with respect to the number of cases and overall mortality. The clinical disease&#xD;
      related to SARS-CoV-2 is referred to as Coronavirus Disease 2019 (COVID-19). Over 2020,&#xD;
      advances were made for treatment of COVID-19 and several vaccinations have received emergency&#xD;
      use authorization for prevention of SARS-CoV-2 infections. However, the pandemic continues to&#xD;
      evolve with new variants and surges of infections in different regions of the world,&#xD;
      requiring an ongoing evidence-generating platform, in particular for the treatment of&#xD;
      COVID-19 infection in the outpatient setting.&#xD;
&#xD;
      This proposed platform protocol can serve as an evidence generating system for prioritized&#xD;
      drugs repurposed from other indications with an established safety record and preliminary&#xD;
      evidence of clinical efficacy for the treatment of COVID-19. The ultimate goal is to evaluate&#xD;
      if repurposed medications can make participants feel better faster and reduce death and&#xD;
      hospitalization.&#xD;
&#xD;
      This platform protocol is designed to be flexible so that it is suitable for a wide range of&#xD;
      settings within healthcare systems and in community settings where it can be integrated into&#xD;
      routine COVID-19 testing programs and subsequent treatment plans. This platform protocol will&#xD;
      enroll participants in an outpatient setting with a confirmed polymerase chain reaction (PCR)&#xD;
      or antigen test for SARS-CoV-2.&#xD;
&#xD;
      Participants will be randomized to study drugs or placebo based on the arms that are actively&#xD;
      enrolling at the time of randomization. Study drugs may be added or removed according to&#xD;
      adaptive design and/or emerging evidence. When there are multiple study drugs available,&#xD;
      randomization will occur based on appropriateness of each drug for the participant as&#xD;
      determined by the study protocol and investigator and participant equipoise. Each participant&#xD;
      will be required to randomize to at least one study drug versus placebo. The probability of&#xD;
      placebo to treatment will remain the same regardless of eligibility decisions.&#xD;
&#xD;
      Eligible participants will be randomized (1:1), in a blinded fashion, to either the study&#xD;
      drug arm or placebo arm in addition to standard of care. As additional study drugs are added,&#xD;
      the randomization will be altered to leverage placebo data across arms. Participants will&#xD;
      receive a complete supply study drug or placebo with the quantity depending on the study&#xD;
      drug/placebo to which they are randomized.&#xD;
&#xD;
      All study visits are designed to be remote. However, screening and enrollment may occur&#xD;
      in-person at sites and unplanned study visits may occur in-person or remotely, as deemed&#xD;
      appropriate by the site investigator for safety purposes. Participants will be asked to&#xD;
      complete questionnaires and report safety events during the study. Participants will be&#xD;
      prompted by the online system to report safety events and these will be reviewed and&#xD;
      confirmed via medical records and site staff, as necessary.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-Blind, Placebo-Controlled, Randomized Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>The participant and study teams will know which study drug the participant is allocated to, but will be blinded to study drug versus placebo because they will be matching.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of hospitalizations as measured by patient reports.</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of deaths as measured by patient reports</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of symptoms as measured by patient reports</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in COVID Clinical Progression Scale</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>COVID Clinical Progression Scale is a scale of 0 to 8, with 0 being &quot;No clinical or virological evidence of infection&quot; to 8 being &quot;death&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospitalizations as measured by patient reports</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths as measured by patient reports</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Symptom Resolutions as measured by patient reports</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Symptom resolution, defined as first of at least three consecutive days without symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life (QOL) as measured by the PROMIS-29</measure>
    <time_frame>Baseline, Day 7, 14, 28, and 29</time_frame>
    <description>The PROMIS-29 consists of seven health domains with four 5-level items associated with each and a pain intensity assessment using a 0-10 numeric rank. The seven health domains include physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite score of hospitalizations, urgent care visits, and emergency room visits as measured by patient reports</measure>
    <time_frame>Up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">15000</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Arm A - Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin - 7-mg tablets&#xD;
Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo -7mg tablets&#xD;
Participant will be instructed to take a pre-specified number of tablets for 3 consecutive days based on their weight for a daily dose of approximately 300-400 µg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Fluvoxamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluvoxamine will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B- Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be self-administered orally by each participant at a dose of 50 mg twice a day for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of fluticasone once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the study drug through the mouthpiece.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is a self-administered inhaled drug. Participants will self-administer 200 µg (1 blister) of placebo once daily for 14 days. After inhaler activation, the powder within the blister is exposed and the participant inhales the placebo through the mouthpiece.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>Each participant will receive a total of twenty 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with &quot;123&quot; over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.</description>
    <arm_group_label>Arm A - Ivermectin</arm_group_label>
    <other_name>Ivermectin Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluvoxamine</intervention_name>
    <description>Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has &quot;APO&quot; and the other side has &quot;F50&quot; with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.</description>
    <arm_group_label>Arm B - Fluvoxamine</arm_group_label>
    <other_name>Fluvoxamine Maleate Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone</intervention_name>
    <description>Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.</description>
    <arm_group_label>Arm C - Fluticasone</arm_group_label>
    <other_name>Fluticasone Furoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each study arm will contain a placebo comparator. Placebo will look similar to study drug and will be administered via the same route of administration and dose. However, placebo will be an inactive substance, containing no study drug.</description>
    <arm_group_label>Arm A - Placebo</arm_group_label>
    <arm_group_label>Arm B- Placebo</arm_group_label>
    <arm_group_label>Arm C - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed Informed Consent&#xD;
&#xD;
          -  Age ≥ 30 years old&#xD;
&#xD;
          -  Confirmed SARS-CoV-2 infection by any authorized or approved polymerase chain reaction&#xD;
             (PCR) or antigen test collected within 10 days of screening&#xD;
&#xD;
          -  Two or more current symptoms of acute infection for ≤7 days. Symptoms include the&#xD;
             following: fatigue, dyspnea, fever, cough, nausea, vomiting, diarrhea, body aches,&#xD;
             chills, headache, sore throat, nasal symptoms, new loss of sense of taste or smell&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior diagnosis of COVID-19 infection (&gt; 10 days from screening)&#xD;
&#xD;
          -  Current or recent (within 10 days of screening) hospitalization&#xD;
&#xD;
          -  Known allergy/sensitivity or any hypersensitivity to components of the study drug or&#xD;
             placebo&#xD;
&#xD;
          -  Known contraindication(s) to study drug including prohibited concomitant medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanna Naggie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sybil Wilson</last_name>
    <phone>1-833-385-1880</phone>
    <email>sybil.wilson@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allison DeLong</last_name>
    <phone>1-833-385-1880</phone>
    <email>allison.hayes@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Trident Health Center</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85382</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madelyn Rosequist</last_name>
      <phone>888-635-0552</phone>
    </contact>
    <investigator>
      <last_name>Arvind Mahadevan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Nguyen</last_name>
      <phone>949-824-3990</phone>
      <email>julie.nguyen@hoag.org</email>
    </contact>
    <investigator>
      <last_name>Philip Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pine Ridge Family Medicine Inc.</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80924</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vigil Vigil</last_name>
      <phone>719-550-5180</phone>
      <email>vecchiarellicrc@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Anthony Vecchiarelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tabitha B. Fortt, M.D., LLC</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anisa Fortt</last_name>
      <phone>203-674-0774</phone>
      <email>afortt-fortt@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Tabitha Fortt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida-JAX-ASCENT</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bowman</last_name>
      <phone>904-244-4691</phone>
      <email>jennifer.bowman@jax.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Taylor Scott</last_name>
      <phone>904-244-4690</phone>
      <email>taylor.scott@jax.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carmen Isache, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunshine Walk In Clinic</name>
      <address>
        <city>Lake Mary</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Moritz</last_name>
      <phone>407-321-7111</phone>
      <email>bstmoritz-gupta@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Anita Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Medical Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Haight</last_name>
      <phone>863-687-1100</phone>
      <email>daniel.haight@mylrh.org</email>
    </contact>
    <investigator>
      <last_name>Steven Guggino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Almanzar</last_name>
      <phone>305-243-5157</phone>
    </contact>
    <contact_backup>
      <last_name>Americo Hajaz</last_name>
      <phone>1-813-205-2006</phone>
      <email>axh1309@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dushyantha Jayaweera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Huerta</last_name>
      <phone>305-665-4818</phone>
      <email>crcwellpharma@cctdoctors.com</email>
    </contact>
    <contact_backup>
      <last_name>Jhonsai Cheng</last_name>
      <email>jcheng@wpharma.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eddie Armas Eddie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovation Clinical Trials Inc.</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Reyes</last_name>
      <phone>305-554-6666</phone>
      <email>lreyes-unger@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Juan Ruiz-Unger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lice Source Services Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33313</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlen Quintero</last_name>
      <phone>954-791-0711</phone>
    </contact>
    <investigator>
      <last_name>Nancy Pyram-Bernard, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Health</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33707</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Burden</last_name>
      <phone>727-345-0160</phone>
      <email>erica@mypremierhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Vijaya Cherukuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igho Ofotokun, MD</last_name>
      <phone>404-616-0659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Essential Medical Care, Inc.</name>
      <address>
        <city>College Park</city>
        <state>Georgia</state>
        <zip>30349</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcella Rogers</last_name>
      <phone>305-665-4818</phone>
      <email>mrogers-james@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Vicki James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>David Kavtaradze MD, Inc.</name>
      <address>
        <city>Cordele</city>
        <state>Georgia</state>
        <zip>31015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cassandra Watson</last_name>
      <phone>229-271-4608</phone>
      <email>cwatson-kavtaradze@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>David Kavtaradze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elite Family Practice</name>
      <address>
        <city>Douglasville</city>
        <state>Georgia</state>
        <zip>30134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teri Hurst</last_name>
      <phone>678-715-2993</phone>
      <email>thurst-burruss@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Valencia Burruss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miller Family Practice, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hawa Wiley</last_name>
      <phone>478-745-7878</phone>
      <email>hwiley-miller@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Conrad Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore Medical Group</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirav Shah, MD</last_name>
      <phone>219-201-8712</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashlie Cornejo</last_name>
      <phone>316-293-1833</phone>
      <email>acornejo@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tiffany Schwasinger-Schmidt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A New Start II, LLC</name>
      <address>
        <city>Central City</city>
        <state>Kentucky</state>
        <zip>42330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raina Vincent</last_name>
      <phone>270-754-3494</phone>
      <email>rainavincent78@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Tim Duke</last_name>
      <phone>270-754-3494</phone>
      <email>tdukes-hardison@cctdoctors.com</email>
    </contact_backup>
    <investigator>
      <last_name>William K Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center- New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wayne Swink</last_name>
      <phone>504-702-4852</phone>
      <email>swink@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Stephen Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jake Hall</last_name>
      <phone>504-842-7413</phone>
    </contact>
    <investigator>
      <last_name>Julia Garcia-Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-1900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Stelmash</last_name>
      <phone>301-754-7556</phone>
      <email>lauren.stelmash@holycrosshealth.org</email>
    </contact>
    <investigator>
      <last_name>Mark Sulkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jadestone Clinical Research, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20855</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Wong</last_name>
      <phone>202-449-6869</phone>
      <email>matthew.wong@jadestonecr.com</email>
    </contact>
    <investigator>
      <last_name>Jonathan Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GFC of Southeastern Michigan, PC</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Koppinger</last_name>
      <phone>313-833-3090</phone>
      <email>nkoppinger-mehta@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Manisha Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Seithel</last_name>
      <phone>573-884-4400</phone>
      <email>seithelm@health.missouri.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Focus Clinical Research Solutions</name>
      <address>
        <city>Bayonne</city>
        <state>New Jersey</state>
        <zip>07002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad Ghaly</last_name>
      <phone>201-788-1372</phone>
      <email>eghaly-gabriel@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Ahab Gabriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Raritan Bay Primary Care &amp; Cardiology Associates</name>
      <address>
        <city>Matawan</city>
        <state>New Jersey</state>
        <zip>07747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Praksha Patel</last_name>
      <phone>732-709-8200</phone>
      <email>pap246@scarletmail.rutgers.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jilu Jose</last_name>
      <email>drjilujose@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Vijay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mediversity Healthcare</name>
      <address>
        <city>Turnersville</city>
        <state>New Jersey</state>
        <zip>08012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pravin Vasoya</last_name>
      <phone>856-740-9777</phone>
      <email>abdulghanicrc@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Ahsan Abdulghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geriatrics and Medical Associates</name>
      <address>
        <city>Clinton</city>
        <state>New York</state>
        <zip>13323</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelina Roche</last_name>
      <phone>315-381-3576</phone>
      <email>aroche-brehaut@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Scott Brehaut, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Salsgiver</last_name>
      <phone>212-746-4089</phone>
      <email>els7021@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew McCarthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spinal Pain and Medical Rehab, PC</name>
      <address>
        <city>Yonkers</city>
        <state>New York</state>
        <zip>10701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sugata Shah</last_name>
      <phone>914-207-1161</phone>
      <email>sshah-shah@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Binod Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vaidya MD PLLC</name>
      <address>
        <city>Clayton</city>
        <state>North Carolina</state>
        <zip>27520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Gould</last_name>
      <phone>919-553-5711</phone>
      <email>tankcrc@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Bhavna Vaidya-Tank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Medical Center, PLLC</name>
      <address>
        <city>Dunn</city>
        <state>North Carolina</state>
        <zip>28334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana Raymond</last_name>
      <phone>910-892-8892</phone>
      <email>oraymond-maria@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Maria Josette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison DeLong</last_name>
      <phone>833-385-1880</phone>
      <email>allison.hayes@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Adrian Hernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>833-385-1880</phone>
    </contact>
    <investigator>
      <last_name>Rowena Dolor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27151</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Williamson, PharmD</last_name>
      <phone>336-713-3431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>TriHealth, Inc</name>
      <address>
        <city>Montgomery</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Daffner</last_name>
      <phone>513-862-5119</phone>
      <email>crystal_daffner@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Martin Gnoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart and Medical Center</name>
      <address>
        <city>Durant</city>
        <state>Oklahoma</state>
        <zip>74701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drew Franklin</last_name>
      <phone>580-931-0500</phone>
      <email>dfranklin-khetpal@cctdoctors.com</email>
    </contact>
    <contact_backup>
      <last_name>Tiffaney Cantrell</last_name>
      <phone>580-931-0500</phone>
      <email>cresstiffaney@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sangeeta Khetpal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Gentile, MD</last_name>
      <phone>215-707-8402</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Serraton-Cazeau</last_name>
      <phone>215-707-8402</phone>
      <email>alex.serraton-cazeau@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Gentile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Klawson</last_name>
      <phone>412-586-9796</phone>
      <email>ekk15@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Akira Sekikawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Ann Szwast</last_name>
      <phone>843-792-4675</phone>
      <email>hinsone@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Lenert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Center of Middle TN</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Slandzicki, MD</last_name>
      <phone>615-205-8351</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Jones</last_name>
      <phone>615-322-0534</phone>
      <email>carly.jones@vumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Susan Sommers</last_name>
      <phone>615-343-1603</phone>
      <email>sue.sommers@vumc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Parul Goyal, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Express Family Clinic</name>
      <address>
        <city>Allen</city>
        <state>Texas</state>
        <zip>75013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De'Ambra Torress</last_name>
      <phone>972-672-4121</phone>
      <email>dtorress-parihar@cctdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Pradeep Parihar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Health Physicians Group</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randall Richwine, MD</last_name>
      <phone>817-732-2878</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Umana</last_name>
      <phone>713-500-6733</phone>
      <email>virginia.e.umana@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Ostrosky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Tragus</last_name>
      <phone>210-203-3539</phone>
      <email>tragus@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Patterson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2021</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Susanna Naggie, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>ivermectin</keyword>
  <keyword>Placebo</keyword>
  <keyword>Duke University Health System</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Duke Clinical Research Institute</keyword>
  <keyword>fluticasone</keyword>
  <keyword>fluvoxamine</keyword>
  <keyword>ACTIV 6</keyword>
  <keyword>ACTIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Xhance</mesh_term>
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Fluvoxamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share this data after it has been de-identified. We will share data beginning around 6 months after publication and for up to 36 months afterward. Access will only be shared with those who have obtained prior IRB approval to be able to access this data.</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Up to 36 months after publication</ipd_time_frame>
    <ipd_access_criteria>Interested investigators will need to seek prior IRB approval before access to any data is granted.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

